| Business Summary | | ICON
plc
is
a
contract
research
organization
(CRO)
providing
clinical
research
and
development
services
on
a
global
basis
to
the
pharmaceutical
and
biotechnology
industries.
The
Company
specializes
in
the
management,
execution
and
analysis
of
complex,
multinational
clinical
trials
in
most
major
therapeutic
areas.
As
of
July
31,
1999,
the
Company
had
operations
in
11
offices
in
eight
countries,
including
the
United
States
and
major
markets
in
Europe
and
the
Pacific
Rim,
and
has
managed
clinical
trials
in
35
countries.
For
the
fiscal
year
ended
May
31,
1999,
the
Company
derived
approximately
58%,
40%
and
2%
of
its
net
revenue
in
the
United
States,
Europe
and
the
Pacific
Rim,
respectively. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ICON
plc
is
a
contract
research
organization
(CRO)
providing
clinical
research
and
development
services
on
a
global
basis
to
the
pharmaceutical
and
biotechnology
industries.
For
the
nine
months
ended
2/28/01,
revenues
rose
45%
to
$84.6
million.
Net
income
rose
from
$3.7
million
to
$7.9
million.
Revenues
reflect
increased
business
from
clients
and
the
acquisitions
of
YRCR,
Protocole
and
UCT.
Earnings
benefited
from
improved
margins
and
the
absence
of
merger
costs. Recent Earnings Announcement For
the
3
months
ended
05/31/2001,
revenues
were
31,545;
after
tax
earnings
were
3,052. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | |
| Position | Ronan Lambe, Ph.D., 60 | Chairman | John Climax, Ph.D., 47 | CEO,
Sec. | Sean Leech | CFO | Peter Gray, 45 | COO,
Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|